Roche (RHHBY) announced it has entered into a U.S. focused collaboration with Pfizer (PFE) to drive awareness and educate on the importance of timely COVID-19 testing, available treatment options, symptoms and the high-risk factors that can increase the chance of progressing to severe illness. "Empowering patients to take appropriate action following a positive test result remains critical to reducing spread of the virus and lowering rates of severe infection," said Thomas Schinecker, CEO of Roche Diagnostics. "As we face another potential winter surge, we are proud to embark on this timely collaboration with Pfizer to improve COVID-19 health literacy among patients in the United States. This exciting initiative may serve as a foundation for future collaborations in many other countries worldwide." The Pilot COVID-19 At-Home Test, distributed in the United States by Roche Diagnostics and manufactured by SD Biosensor, will now include a QR code that directs individuals to covid19knowmore.com, where they can learn more about COVID-19, including CDC guidance on testing and treatment options.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- Roche announces U.S. collaboration with Pfizer to help patients who test positive for COVID-19 navigate risks, symptoms, testing and treatment options
- Genentech presents data on glofitamab, mosunetuzumab potential at ASH 2022
- Roche presents new data demonstrating the potential benefit of glofitamab and Lunsumio as fixed-duration, off-the-shelf treatment options for lymphoma
- Roche presents new and updated data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022
- [Ad hoc announcement pursuant to Art. 53 LR] Roche: Changes in the Board of Directors and the Corporate Executive Committee
